Details

Last Funding Type

Series B

Last Funding Money Raised

$11.10M

Industries

Biotechnology,Health Diagnostics,Medical,Therapeutics

Founded date

May 20, 2015

Number Of Employee

51 - 100

Operating Status

Active

APRINOIA is a late-stage biotechnology company committed to protecting patients' brain health and changing outcomes of neurodegenerative diseases through first-in-class and best-in-class diagnostic tools and novel therapies. The company aims to bring precision medicine to neuroscience by identifying and targeting the protein aggregates of tau, alpha-synuclein and other proteins that play a critical role in the pathogenesis of many neurodegenerative diseases, such as Alzheimer's and Parkinson's Diseases. The company currently has operations in Hong Kong, Suzhou, Shanghai, Tokyo, and Boston.